American Oncology Network announced that several research studies, co-authored by AON physicians and leaders, were accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The meeting was held from May 31 to June 4 in Chicago. The following abstracts were selected for either poster discussions, presentations or online publication after rigorous review.

Ruemu Ejedafeta Birhiray, MD, of Hematology Oncology of Indiana, co-authored the following studies: Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator?s choice in previously untreated follicular lymphoma (OLYMPIA-1). Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2). Ralph V. Boccia, MD, FACP, of The Center for Cancer and Blood Disorders, co-authored the following studies: Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy. Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6. Arvind Chaudhry, MD, PhD, of Summit Cancer Centers, co-authored the following studies: BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Phase 1 trial of TU2218, TGFß-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors. YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial. A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.

Christopher Chay, MD, of Messino Cancer Centers, co-authored the following study: Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy. Stephen ?Fred? Divers, MD, of Genesis Cancer and Blood Institute and AON?s chief medical officer, and Brian Mulherin, MD, of Hematology Oncology of Indiana, co-authored the following study: Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx).

Tamara Weinberg, RN, BSN, OCN, ONN-CG, AON?s pharmacy RN supervisor, authored the following study, which will be published only on the ASCO website: Can a medically integrated oncology pharmacy decrease waste and avoidance?. ASCO is a leading professional organization for oncology physicians and professionals. The annual meeting brings together oncology physicians and thought leaders for networking opportunities and more than 145 hours of educational and informational sessions.

AON has many practices that are actively engaged in clinical research initiatives, with four sites designated as strategic research sites for Sarah Cannon Research Institute. As part of commitment to advancing medical knowledge and patient care, AON practices provide opportunities for participation in over 150 clinical trials. These services are conveniently accessible at a community level, ensuring patients receive cutting-edge treatments close to home, enhancing their overall cancer journey.